GSK’s multiple myeloma ADC Blenrep was pulled from the market. Now, it’s poised for a comeback.
GSK’s cancer drug failed a confirmatory trial two years after an accelerated approval, but impressive new survival data could ...
FiercePharma2d
ASH: With survival win against J&J's Darzalex, GSK bolsters case for return of myeloma ADC Blenrep
Based on DREAMM-7 and another positive phase 3 trial, DREAMM-8 for Blenrep’s combination with Bristol Myers Squibb’s Pomalyst ...
MM&M2d
GSK highlights positive Blenrep data from Phase 3 trial at ASH
GSK announces success of their drug Blenrep at reducing the risk of death in patients diagnosed with multiple myeloma.
GSK's drug combo shown to cut risk of death by 42% in type of blood cancer
British drugmaker GSK said on Monday its experimental cancer drug Blenrep in combination with other treatments reduced the ...
pharmaphorum2d
ASH: Blenrep ups survival by 42% in multiple myeloma trial
The data reported at ASH revealed a 74% OS rate in the Blenrep plus BorDex (BVd) arm of DREAMM-7 versus a 60% rate with ...
GSK Gets Positive Results in Blood-Cancer Drug Trial
Blenrep, in combination with other drugs, reduced the risk of death by 42% in patients with multiple myeloma whose first ...
GSK's Blood Cancer Drug Shows Improved Survival Compared To Johnson & Johnson's Darzalex
GSK plc (NYSE:GSK) announced statistically significant and clinically meaningful overall survival (OS) results from a planned ...
STAT2d
GSK myeloma medicine improves survival in trial, another step in the drug’s revival
GSK last month announced that Blenrep had succeeded in improving overall survival in the trial, called DREAMM-7. The detailed ...
GSK announces NMPA of China accepted review of NDA for Blenrep
GSK (GSK) announced that the National Medical Products Administration, NMPA, of China has accepted for review a new drug application, NDA, for ...
Daily1d
Blenrep combo accepted for priority review in China in relapsed/refractory multiple myeloma: GSK
London: GSK plc has announced that the National Medical Products Administration (NMPA) of China has accepted for review a new ...
STAT2d
Johnson & Johnson seeks first drug approval for treatment of smoldering myeloma
Market analysts liked the news, with analysts for Cantor writing that this was a “best-case data update.” ...
GSK's Nucala and Blenrep receive regulatory boost in US and China
In addition, GSK said its Blenrep drug has been approved for priority review in China to treat sufferers of myeloma, a bone marrow cancer. The regulatory submission is supported by phase III ...